Phase 1 Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT07416383 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 1 Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT07416383
Not Yet Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with moderate-to-severe inflammatory bowel disease (IBD)
  • Your IBD has been hard to treat — meaning at least two different types of biologic or small molecule medications have not worked for you, OR you have had at least two bowel surgeries that did not resolve your condition
  • Your bone marrow and major organs (such as liver and kidneys) are working well enough to participate
  • You are not pregnant and are not planning to become pregnant during the trial
  • You are willing to take part in the study

Who may not be able to join:

  • You currently have an active infection, a hidden (latent) infection, a serious infection in the last two weeks, or a cancer diagnosis
  • You have taken part in another clinical trial within the last four weeks
  • You are taking other medications alongside this treatment, except for a low dose of steroid (glucocorticoid)
  • You have recently had abdominal surgery or received a live vaccine (confirm with trial site for exact timeframes)
  • You have any surgery planned within the next three months
  • The trial researchers have determined for any other reason that participation would not be appropriate for you (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13757118653

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
31 December 2030

Primary endpoints

maximum tolerant dose(MTD); rate of DLT(dose-limiting toxicity)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov